key: cord-0798034-w0t47sn7 authors: Hata, Masahiro; Fujimoto, Michiko; Kanai, Koji; Yoshiyama, Kenji; Nakatani, Yoshitaka; Nakabayashi, Daiji; Maemura, Saki; Kawata, Shinya; Hakozaki, Takaaki; Nishikura, Shuya; Umemoto, Aiko; Sasada, Toru; Iwata, Kazuhiko; Tanaka, Hideki; Mamoto, Akiko; Toi, Yuuki; Taniguchi, Norio; Saito, Makiko; Kimura, Yoshio; Kishimoto, Kazuko; Hayami, Megumi; Ikeda, Manabu title: No adverse events were observed in clozapine‐treated patients on extended hematologic monitoring intervals during the coronavirus pandemic in four psychiatric centers in Japan date: 2021-02-19 journal: Neuropsychopharmacol Rep DOI: 10.1002/npr2.12166 sha: ee21a808ef5fc9f086f119b94e4d0dfc8822ff18 doc_id: 798034 cord_uid: w0t47sn7 AIM: As an emergency measure during the coronavirus disease pandemic, the monitoring interval for clozapine use was temporarily extended beyond the regulatory requirement in Japan, which is the safest monitoring interval worldwide. In this study, we aimed to explore the effect of this measure on patients undergoing clozapine treatment. METHODS: This retrospective chart review study included patients with treatment‐resistant schizophrenia (TRS) who were undergoing clozapine treatment at four psychiatric institutions in Japan. Demographic characteristics and clinical information of these patients were collected on April 27, 2020, when Japanese psychiatrists were virtually allowed to prescribe clozapine beyond the regulatory requirement. Furthermore, information of adverse events related to the emergency measure was collected and analyzed. RESULTS: Of the 41 patients with TRS included in this study, 19 patients underwent extended hematological monitoring during clozapine treatment. No psychiatric or hematological adverse events were observed in the patients during the extended monitoring interval. CONCLUSION: This study suggested that there were few adverse events of clozapine‐treated patients related to emergency measures in Japan. However, hematological monitoring intervals during clozapine treatment have been emergently extended worldwide; hence, it is necessary to verify the results of these measures. Clozapine is currently the most effective antipsychotic for treatmentresistant schizophrenia (TRS). 1 The clinical guidelines in several countries, 2, 3, 4 including Japan, 5 recommend clozapine for the management of TRS. Although clozapine treatment is clinically useful, it is associated with agranulocytosis, a serious life-threatening adverse event. 6 Hence, frequent hematological monitoring is needed during clozapine treatment for early detection of agranulocytosis. The regulatory requirement for hematological monitoring during clozapine treatment in Japan is the most frequent and safest worldwide. In Japan, the hematological monitoring interval is regulated at a maximum of 7 days when the clozapine treatment period is 1-26 weeks and a maximum of 14 days when the period exceeds 26 weeks. 7 The frequency of hematological monitoring adopted in a relatively large number of countries is weekly for the first 18 weeks and once a month thereafter. 1 One of the reasons for the strict national regulations regarding the monitoring of patients undergoing clozapine treatment could be a higher frequency of clozapine-induced agranulocytosis reported in Japanese clinical trials than in clinical trials from Europe and the United States. 8 Another reason is the late launch of clozapine in Japan. In Japan, clozapine has been available since 2009; hence, the experience of psychiatrists regarding clozapine treatment is limited. 1 However, prescribing data have been accumulated for >10 years, and no deaths due to agranulocytosis in >1800 clozapine-treated cases were reported in a postmarketing surveillance in Japan. 9 To reduce the burden on patients undergoing frequent hematological monitoring, the necessity of reconsidering the hematological monitoring interval during clozapine treatment has been discussed in Japan. 10 An outbreak of coronavirus disease (COVID-19) emerged in China in the late 2019 and became a pandemic by 2020. Under these circumstances, on March 23, 2020, the document "Clozapine -Emergency protocol for: Patients on monthly monitoring" 11 published by the Royal College of Psychiatrists recommended to extend the hematological monitoring interval for patients undergoing clozapine treatment and meeting the following criteria: drug continuation for >1 year, absolute neutrophil count never <2000/μL, no safe access to hematological testing, and a high risk of deterioration of psychosis after discontinuing clozapine treatment. Subsequently, the consensus statement on the use of clozapine during the COVID-19 pandemic 12 was published online on April 3, 2020. It recommended that the frequency of hematological monitoring during clozapine treatment can be reduced to once every 3 months. In Japan, on April 10, 2020, the document titled "Requests for the emergency measures regarding monitoring interval of clozapine use when requesting to refrain from going out or invoking lockdown instruction by the government" 13 pandemic. Subsequently, all doctors certified to prescribe clozapine received an e-mail from the center-in-charge of clozapine use in Japan on April 27, 2020, and the hematological monitoring interval during clozapine treatment was virtually extended up to 42 days. However, the effect of this emergency measure on patients undergoing clozapine treatment is uncertain. Hence, in this study, we aimed to explore the psychiatric and hematological adverse events in patients undergoing extended hematological monitoring during clozapine treatment due to the COVID-19 pandemic and verify the validity of this urgent measure based on retrospective chart review in four psychiatric centers in Japan. This retrospective chart review study included patients with TRS undergoing clozapine treatment at four psychiatric institutions in Japan-Osaka University Hospital (OUH), Osaka Psychiatric Medical Center (OPMC), Asakayama General Hospital (AGH), and Kosaka Hospital (KH). All patients were diagnosed with TRS based on the Japanese clinical guidelines 7 by certified psychiatrists and prescribed clozapine. Demographic characteristics and clinical information of these patients, including age, sex, usage, and duration of clozapine treatment, were collected on April 27, 2020, when Japanese psychiatrists were virtually allowed to prescribe clozapine beyond the regulatory requirement. Clozapine was prescribed for patients with TRS. The diagnostic criteria of TRS included poor response and tolerance to other antipsychotics based on the clozapine pharmaceutical reference in Japan. 7 The poor response criterion was defined as the failure to respond (never reached ≥41 points in the Global Assessment of Functioning) to a sufficient dose (>600 mg/d chlorpromazine equivalent) of at least two well-tolerated antipsychotics with sufficient treatment duration (at least 4 weeks). 14 The poor tolerance criterion was defined as the failure to adequately respond to monotherapy of at least two antipsychotics due to failure in increasing the adequate treatment dose for reasons such as the occurrence or worsening of moderate or severe tardive dyskinesia, tardive dystonia, or other tardive extrapyramidal symptoms or occurrence of uncontrollable parkinsonism, akathisia, or acute dystonia. 14 We used the chi-square test and Fisher's exact test to compare the demographic and clinical data of patients treated at the four psychiatric centers and analyze the adjusted standardized residuals. Analysis of variance was used to determine whether differences existed among the four psychiatric centers with regard to patient characteristics, and the Bonferroni post hoc test was used for adjusting multiple comparison situations. The threshold for significance was set at P = .05. Statistical analyses were conducted using SPSS software version 25.0. The demographic and clinical characteristics of patients with TRS undergoing clozapine treatment on April 27, 2020, are shown in Table 1 were treated with clozapine due to poor response to antipsychotics, and only one patient was treated with clozapine due to poor tolerance. Sex, age, and clozapine dosage were not statistically different among patients treated at the four institution. However, a significant difference was observed in the duration of clozapine therapy (P = .019); patients treated at OUH had significantly longer duration of clozapine therapy than those treated at AGH and KH (P = .049 and P = .038, respectively, after Bonferroni correction). The baseline risk of severe neutropenia during clozapine administration was estimated to be 1.3% overall, with peak risk around 1 month after initiation and substantial decline in risk at 18 weeks. 15 Afterward, the risk of neutropenia was estimated to be 0.70/1000 patient-years for the clozapine treatment period of 6-12 months and 0.39/1000 patient-years after 12 months from clozapine initiation. 16 This risk was considered very similar to that with other firstgeneration antipsychotics (0.1-1.1/1000 patients-years). 16 However, in a previous study, patients diagnosed with a mental disorder had an increased risk of COVID-19, especially in those diagnosed with schizophrenia. 19 This could be explained by the overlapping biological factors of schizophrenia and COVID-19. 19 One of the common biological factors was inflammation, which has been reported to play a role in the pathogenesis of schizophrenia 20 and in the systemic manifestations of COVID-19. 21 In addition, patients with schizophrenia and COVID-19 were reported to have higher rate of mortality and hospitalization, 19 which might have resulted from medical comorbidities and a variety of socioeconomic and diseaserelated factors. 19 For instance, individuals with mental disorders have a higher risk of substance use disorders than the general population. 19 In particular, tobacco smoking was highly prevalent among patients with schizophrenia compared to the general population, 22 which accelerated the pulmonary pathology risk, leading to severe COVID-19. 19 In addition, patients receiving clozapine were reported to be significantly more susceptible to COVID-19 than patients receiving other antipsychotics. 23 Furthermore, clozapine-treated patients were reported to have a higher risk of pneumonia and pneumonia with fatal outcomes than patients treated with other secondgeneration antipsychotics. 24 COVID-19 imposed critical challenges for medical care worldwide. 25 The effects of the pandemic and related restrictions on healthcare contact are likely to be long-lasting and wide-ranging. 25 The restrictions related to the COVID-19 pandemic have urged clinicians and patients to reappraise medical care. 25 Prefecture in Japan; our findings could not reflect the general situation in Japan. Therefore, future studies including larger sample sizes and more institutions in Japan or the world are necessary. Another concern was the omission of inspection for COVID-19, particularly asymptomatic cases that could not be captured in regular clinical settings. In conclusion, the hematological monitoring interval during clozapine treatment was temporarily extended beyond the regulatory requirement in Japan due to the COVID-19 pandemic. No psychiatric or hematological adverse events were observed in clozapine-treated patients in this study. Hematological monitoring intervals during clozapine treatment have been extended worldwide during the pandemic; hence, it is necessary to analyze the data of patients undergoing extended hematological monitoring interval during clozapine treatment in detail and carefully verify the effects of these emergency measures. This work was supported by JSPS KAKENHI, Grant Number JP20K07945. The authors of this article declare no conflict of interest. This study was approved by the Ethics Committee of Osaka University Hospital, Japan. The study protocol was fully explained to all patients by the doctors in charge before recruitment. Informed consent was obtained from all patients included in this manuscript, and privacy protection has been completely ensured in the case description. N/A. N/A. The data that support the findings of this study are available from the corresponding author upon reasonable request. The raw data belonged to the present study cannot be made publicly available, because the disclosure of personal data was not included in the research protocol of the present study. https://orcid.org/0000-0003-3837-1504 International trends in clozapine use: a study in 17 countries World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia, Part 1: Acute treatment of schizophrenia Practice guideline for the treatment of patients with schizophrenia, second edition National Collaborating Centre for Mental Health: Schizophrenia: the NICE guideline on core interventions in the treatment and management of schizophrenia in primary and secondary care; National Clinical Practice Guidelines Number CG82 Guideline for Pharmacological Therapy of Schizophrenia Optimizing clozapine treatment Worldwide differences in clozapine use The role of CPMS in clozapine treatment Regulations of clozapine use: comparing Japan with other countries Emergency protocol for: patients on monthly monitoring (Internet) Consensus statement on the use of clozapine during the COVID-19 pandemic Requests for the emergency measures regarding monitoring interval of clozapine use when requesting to refrain from going out or invoking lockdown instruction by the government (Internet) Clozapine-induced seizures, electroencephalography abnormalities, and clinical responses in Japanese patients with schizophrenia Guide to the management of clozapine-related tolerability and safety concerns Risk of clozapine-associated agranulocytosis and mandatory white blood cell monitoring Systematic review: agranulocytosis induced by nonchemotherapy drugs Can the examination interval be extended under clozapine administration? Increased risk of COVID-19 infection and mortality in people with mental disorders: analysis from electronic health records in the United States. World Psychiatry Inflammation in schizophrenia: pathogenetic aspects and therapeutic considerations Psychiatric face of COVID-19 Cigarette smoking by patients with serious mental illness, 1999-2016: an increasing disparity Clozapine treatment and risk of COVID-19 infection: retrospective cohort study Pneumonia may be more frequent and have more fatal outcomes with clozapine than with other second-generation antipsychotics Covid-19 and mental health: a transformational opportunity to apply an evidence-based approach to clinical practice and research Clozapine treated patients and COVID-19: ensuring continued care through collaboration